Switzerland-based pharmaceutical company, Novartis has launched the drug, Scapho for the treatment of plaque psoriasis in India.
Psoriasis is a severe, non-contagious autoimmune skin disease, characterized by red scaly patches covered with white scales. Plaque psoriasis is a more serious form of the condition.
The generic name of Scapho is secukinumab, which is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India for the treatment of moderate-to-severe plaque psoriasis in adult patients.
"This approval marks a significant milestone in the treatment of psoriasis, providing a new and important first-line biologic treatment option for patients who are candidates for systemic therapy," Novartis said in a statement.